COMMUNIQUÉS West-GlobeNewswire

Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences

01/05/2025 - 10:00

ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases [...]

Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences

01/05/2025 - 10:00

ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases [...]

AB Science publiera son rapport financier annuel 2024 le vendredi 9 mai 2025

01/05/2025 - 10:06

COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE LA PUBLICATION LE 9 MAI 2025 DE SON RAPPORT FINANCIER ANNUEL 2024 Paris, 1 er mai 2025, 10h AB Science SA (Euronext - FR0010557264 - AB) annonce aujourd'hui le décalage de la [...]

AB Science will publish its 2024 annual financial report on May 9, 2025

01/05/2025 - 10:06

PRESS RELEASE THE COMPANY WILL PUBLISH ITS 2024 ANNUAL FINANCIAL REPORT ON 9 MAY 2025 Paris, May 1 st 2025, 10am CET AB Science SA (Euronext - FR0010557264 - AB) today announced that it has postponed the publication of [...]

PhenQ Reviews: Can This Thermogenic Fat Burner Help You Burn Fat? A Detailed Report By Riti Health Experts

01/05/2025 - 11:00

Read the latest PhenQ review from Riti Health experts. Find out if this popular thermogenic fat burner can boost energy and help you burn stubborn fat. Dover, Delaware, May 01, 2025 (GLOBE NEWSWIRE) -- Fat-burning [...]

Taux de cancer en hausse : les dermatologues tiennent au mois de mai leur campagne nationale sur la prudence au soleil

01/05/2025 - 12:00

L’Association canadienne de dermatologie insiste sur l’importance de se protéger du soleil dans le cadre de sa campagne Prudence sous le soleil du Nord, en mettant l’accent sur l’ombrage, la prévention et la détection [...]

As Skin Cancer Rates Climb, Canadian Dermatologists Champion Sun Safety Nationwide this May

01/05/2025 - 12:00

The Canadian Dermatology Association highlights sun safety in the True North, with a focus on shade, prevention, and early detection. OTTAWA, Ontario, May 01, 2025 (GLOBE NEWSWIRE) -- As the warmth of the sun returns [...]

Biosplice Announces First Patient Dosed in Phase 2 Trial of Cirtuvivint for Advanced Soft-Tissue Sarcomas

01/05/2025 - 12:00

Multicenter study sponsored by SELNET to evaluate cirtuvivint as a second-line monotherapy in selected sarcoma subtypes SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical- [...]

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

01/05/2025 - 12:01

4WARD Phase 3 chronic neutropenia trial in full swing; full enrollment on track for 3Q or 4Q 2025 and top-line data in 2H 2026 Additional analyses of mavorixafor clinical trial data increase confidence in successful [...]

Coloplast A/S Revised guidance for FY 2024/25

01/05/2025 - 12:23

Coloplast revises financial guidance for FY 2024/25 and pre-announces H1 2024/25 key financial figures Coloplast revises the guidance on organic growth and EBIT margin before special items for FY 2024/25. The organic [...]

Teleflex Reports First Quarter Financial Results and Full Year 2025 Outlook

01/05/2025 - 12:30

WAYNE, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended March 30, 2025. First quarter financial summary Revenues of $ [...]

Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

01/05/2025 - 12:30

– U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND ® (mitapivat) in Thalassemia, with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease On Track, with [...]

FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain

01/05/2025 - 13:00

LONDON and NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an [...]

Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025

01/05/2025 - 13:00

Panel to Discuss Current Challenges Encountered by Patients with HCV , Results from Atea’s Phase 2 Study of the Regimen of Bemnifosbuvir and Ruzasvir, and What a New Optimized HCV Therapy Could Provide for Prescribers [...]

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025

01/05/2025 - 13:00

― Enrollment complete in the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); initiated the 20 mg dose cohort ― ― On track to provide clinical data from the 12 mg dose [...]

Sol-Gel Announces Reverse Share Split

01/05/2025 - 13:00

NESS ZIONA, Israel, May 01, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (the “Company”) (NASDAQ: SLGL), a clinical-stage dermatology company, today announced a reverse share split (the “Reverse Split”) of the [...]

Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates

01/05/2025 - 13:00

First-quarter 2025 Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as [...]

Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET

01/05/2025 - 13:00

WARREN, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]

Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

01/05/2025 - 13:00

BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report first quarter 2025 financial results on May 12, 2025, before the open of the U.S. financial markets. [...]